Testosterone & Prostate Cancer
The Saturation Model and the Overturned 70-Year Fear
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (clinical concept, not a product)
Reference only. Not medical advice.
What can go wrong
This is a clinical-judgment area, not a green light. Men with active, untreated, or high-risk prostate cancer are not standard TRT candidates, and TRT in men on active surveillance or after definitive treatment is investigational and must be specialist-supervised with PSA monitoring. The saturation model lowers - but does not eliminate - uncertainty.
This is something to take to a clinician. The Atlas can tell you what is known about testosterone & prostate cancer in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
For most of the 20th century, clinicians believed exogenous testosterone would accelerate prostate cancer, so hypogonadal men were routinely denied treatment. The Saturation Model, articulated by Harvard urologist Abraham Morgentaler around 2008-2009, proposes that the prostate's androgen receptors become saturated at relatively low testosterone concentrations - by one common estimate near the 250 ng/dL range - so that further increases produce little additional growth signal. Modern evidence has not shown that testosterone therapy raises prostate cancer incidence, though the question remains nuanced and active surveillance/treated patients require individualized judgment.
The dogma that testosterone 'feeds' prostate cancer was built on a single patient.
What it is invoked to explain
Claims this idea is used to support. Whether it supports them is the rest of the entry.
How it works
Androgen-dependent prostate tissue responds to testosterone via the androgen receptor (AR). The Saturation Model holds that AR binding approaches maximal occupancy at low serum testosterone, so growth stimulation plateaus; below the saturation threshold the tissue is androgen-sensitive, above it the dose-response curve flattens. This is offered to explain why castrate-level testosterone shrinks prostate cancer (Huggins' real and durable finding) while raising testosterone from low to normal does not appear to drive comparable growth.
What the saturation model does not claim
The model is frequently overstated online to mean 'testosterone is safe for everyone, even with cancer.' That is not what the evidence supports. The saturation concept addresses why physiological replacement does not behave like rocket fuel for the prostate; it does not license supraphysiological dosing, nor does it settle whether TRT is appropriate in men with untreated or high-risk prostate cancer. The threshold figure itself is an estimate and has been challenged in the literature.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Decisions about testosterone therapy in any man with a prostate cancer history must be individualized by a urologist or endocrinologist; self-directed TRT carries documented risks.
What people get wrong
Often saidTestosterone therapy causes prostate cancer
ActuallyLarge reviews and the TRAVERSE trial have not demonstrated an increase in prostate cancer incidence with testosterone therapy in hypogonadal men. The original fear rested on a 1941 conclusion drawn from one patient.
Often saidBecause castration shrinks prostate cancer, raising testosterone must grow it proportionally
ActuallyThis is the logical leap the saturation model challenges. The dose-response is not linear across the full range; the tissue appears saturated at low testosterone.
Who profits, and who pushes back
Critics in International/Investigative Urology letters
Letters published around 2020 questioned the strength of the evidence behind the saturation threshold, arguing the data are weaker than the model's popular reputation implies.
How we got here
Charles Huggins won the 1966 Nobel Prize for showing that androgen deprivation regresses metastatic prostate cancer - a genuine, life-extending discovery. The damaging corollary, that giving testosterone would accelerate cancer, was attached largely on the basis of a single 1941 patient. From roughly 1941 to 1991 testosterone use in the United States was minimal, and hypogonadal men were widely denied treatment. Morgentaler's archival re-reading of the original papers reopened the question and seeded the saturation model.
- 1941Huggins & Hodges report androgen deprivation regresses prostate cancer; testosterone-progression claim from one patient
- 1966Huggins awarded Nobel Prize
- 2006Morgentaler publishes 'modern myth' historical critique
- 2008-2009Saturation Model articulated
- 2020Published letters question the threshold's evidentiary basis
- 2023TRAVERSE shows no prostate cancer excess
At a glance
- Origin of fear
- Huggins & Hodges, 1941
- Saturation concept
- Morgentaler, ~2006-2009
- Proposed saturation point
- ~250 ng/dL (estimate, contested)
- TRAVERSE prostate cancer
- 0.5% T vs 0.4% placebo
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Testosterone & Prostate Cancer. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Morgentaler & Traish - Saturation Model review2009
Proposed that prostate growth is androgen-sensitive only up to a low saturation point, reframing decades of fear
Morgentaler - 'Historical Perspective on a Modern Myth'2006
Traced the 'testosterone feeds prostate cancer' dogma to Huggins & Hodges 1941, whose progression claim rested on essentially a single non-castrated patient
TRAVERSE prostate substudy2023
Prostate cancer occurred in 0.5% of testosterone vs 0.4% of placebo men over ~33 months - no significant excess